|
**Overview**: Human Leukocyte Antigen PRA Class II Panel**Introduction**: The Human Leukocyte Antigen PRA Class II Panel is a diagnostic tool designed to assess transplant rejection risk using serum samples. In India, PRA Class II measures sensitization to MHC Class II antigens, crucial for kidney/heart/lung transplantation where Class II antibodies correlate with chronic rejection. High morbidity from under-testing in rural/low-SES transplant candidates, limited labs, delayed desensitization leading to antibody-mediated rejection or graft loss. Per immunology practices aligned with ICMR and Indian Society of Organ Transplantation guidelines, the test employs immunoassay for PRA Class II antibodies (quantitative) over 1-2 days with high accuracy, valuable for pre-transplant risk assessment. This diagnostic falls under transplant screening and targets potential recipients (retransplant, multiparous women), addressing accurate detection to guide donor matching or plasmapheresis. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise sensitization profiling and improving graft survival. Its serum-based approach ensures reliable antibody detection.**Other Names**: HLA PRA II Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: PRA Class II standard; in India, used in transplant immunology.**Purpose**: The test assesses 2 parameters including PRA Class II antibodies to guide transplant rejection risk assessment, quantify sensitization, inform donor selection.**Test Parameters**: 1. PRA Class II Antibodies, 2. Quantitative Result.**Pretest Condition**: No fasting required; patients should be transplant candidates.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on prior transplants, transfusions, pregnancies.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected sensitization including rejection, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent transfusion can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High PRA Class II indicates chronic rejection risk, necessitating specialist input.**Specialist Consultation**: Transplant immunologists should be consulted for management.**Additional Supporting Tests**: Single antigen bead, crossmatch for confirmation.**Test Limitations**: Quantitative only; comprehensive approach required.**References**: Indian Journal of Transplantation 2024, Transplant Studies India 2023. |
